Aptose Biosciences Inc

APTOF
$1.69 (+ $0.00 + 0.00%)
Last updated: Previous Close (2026-07-25)
APTOF Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealth Care
IndustryBiotechnology
ISINCA03835T4081
Market Price1.69
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPSN/A
Market Cap$4.3M
Book Value-13.58
Price to BookN/A
BetaN/A
52w High1.81
52w Low1.01
Next Earnings DateN/A

Aptose Biosciences Inc trades under ticker APTOF on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Health Care exposure. Identifiers: ISIN CA03835T4081. Also searched as Aptose Biosciences.

Related researchAPTOF stock priceAPTOF share priceAptose Biosciences stockAptose Biosciences share price
About the Company
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Price History